Home » Stocks » IMARA Inc.


Stock Price: $24.37 USD -0.68 (-2.70%)
Updated Jul 9, 2020 1:14 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 421.04M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 17.28M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 9, 2020
Last Price $24.37
Previous Close $25.04
Change ($) -0.68
Change (%) -2.70%
Day's Open 24.93
Day's Range 23.47 - 25.11
Day's Volume 24,681
52-Week Range 13.40 - 62.71

More Stats

Market Cap 421.04M
Enterprise Value 315.17M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 17.28M
Float 3.94M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 76,973
Short Ratio 0.76
Short % of Float 1.02%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.68
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 105.87M
Net Cash / Share 6.13
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -73.52%
ROE -47.69%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(81.94% upside)
Current: 24.37
Target: 44.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-24.12-10.68
Net Income-23.46-11.34
Shares Outstanding0.700.70
Earnings Per Share-33.40-16.14
Operating Cash Flow-21.88-8.78
Capital Expenditures-0.14-
Free Cash Flow-22.02-8.78
Cash & Equivalents28.917.38
Net Cash / Debt28.917.38
Book Value-48.85-26.32
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name IMARA Inc.
Country United States
Employees 16
CEO Rahul D. Ballal

Stock Information

Ticker Symbol IMRA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IMRA


Imara, Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, which is an oral, once-a-day therapeutic for the treatment of sickle cell disease and b-thalassemia. The company was founded in 2016 and is headquartered in Boston, Massachusetts.